BioNTech Net Receivables vs Accounts Payable Analysis

0A3M Stock

USD 110.25 4.06 3.55%

BioNTech financial indicator trend analysis is way more than just evaluating BioNTech SE prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNTech SE is a good investment. Please check the relationship between BioNTech Net Receivables and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Net Receivables vs Accounts Payable

Net Receivables vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNTech SE Net Receivables account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between BioNTech's Net Receivables and Accounts Payable is 0.47. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of BioNTech SE, assuming nothing else is changed. The correlation between historical values of BioNTech's Net Receivables and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of BioNTech SE are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Receivables i.e., BioNTech's Net Receivables and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.47

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Net Receivables

Accounts Payable

An accounting item on the balance sheet that represents BioNTech obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of BioNTech SE are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from BioNTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

The value of Tax Provision is estimated to slide to about 243 M. The value of Selling General Administrative is expected to slide to about 293.8 M

	2021	2022	2023	2024 (projected)
Gross Profit	15.1B	12.8B	3.2B	5.8B
Total Revenue	19.0B	17.3B	3.8B	7.5B

Gross Profit Total Revenue

BioNTech fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Inventory	Other Current Assets	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Cash	Non Current Assets Total	Non Currrent Assets Other	Good Will	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Total Liab	Net Invested Capital	Long Term Investments
Other Current Liab		0.92	0.45	0.73	0.58	0.46	0.33	0.99	0.89	0.53	0.68	0.7	0.59	0.71	0.7	0.62	0.4	0.31	0.14	0.26	0.59	0.17	0.43	0.9	0.62	0.14
Total Current Liabilities	0.92		0.62	0.89	0.81	0.68	0.6	0.94	1.0	0.77	0.82	0.89	0.75	0.87	0.92	0.83	0.68	0.55	0.38	0.48	0.66	0.4	0.62	1.0	0.84	0.38
Other Liab	0.45	0.62		0.58	0.59	0.5	0.3	0.53	0.65	0.48	0.27	0.59	0.2	0.45	0.69	0.58	0.5	0.4	0.35	0.36	0.19	0.35	0.62	0.63	0.58	0.35
Net Tangible Assets	0.73	0.89	0.58		0.97	0.93	0.82	0.75	0.91	0.94	0.91	0.99	0.81	0.98	0.94	0.98	0.88	0.86	0.75	0.81	0.83	0.76	0.75	0.93	0.98	0.75
Retained Earnings	0.58	0.81	0.59	0.97		0.95	0.89	0.62	0.84	0.98	0.86	0.99	0.75	0.94	0.93	1.0	0.96	0.9	0.8	0.85	0.8	0.8	0.7	0.84	1.0	0.8
Accounts Payable	0.46	0.68	0.5	0.93	0.95		0.92	0.47	0.72	0.96	0.86	0.91	0.75	0.93	0.83	0.95	0.9	0.98	0.92	0.96	0.84	0.92	0.8	0.74	0.94	0.92
Other Assets	0.33	0.6	0.3	0.82	0.89	0.92		0.34	0.63	0.96	0.87	0.85	0.78	0.88	0.79	0.89	0.93	0.91	0.81	0.86	0.82	0.8	0.65	0.65	0.88	0.8
Net Receivables	0.99	0.94	0.53	0.75	0.62	0.47	0.34		0.91	0.55	0.66	0.73	0.57	0.71	0.74	0.65	0.45	0.33	0.16	0.26	0.57	0.19	0.42	0.92	0.66	0.16
Inventory	0.89	1.0	0.65	0.91	0.84	0.72	0.63	0.91		0.8	0.84	0.91	0.78	0.89	0.95	0.86	0.72	0.6	0.44	0.54	0.65	0.45	0.67	1.0	0.87	0.44
Other Current Assets	0.53	0.77	0.48	0.94	0.98	0.96	0.96	0.55	0.8		0.9	0.96	0.8	0.95	0.91	0.98	0.97	0.92	0.8	0.86	0.84	0.8	0.7	0.81	0.98	0.8
Other Stockholder Equity	0.68	0.82	0.27	0.91	0.86	0.86	0.87	0.66	0.84	0.9		0.89	0.95	0.97	0.85	0.88	0.79	0.81	0.67	0.77	0.85	0.68	0.7	0.86	0.88	0.67
Total Current Assets	0.7	0.89	0.59	0.99	0.99	0.91	0.85	0.73	0.91	0.96	0.89		0.79	0.96	0.96	0.99	0.93	0.84	0.71	0.78	0.81	0.71	0.68	0.91	0.99	0.71
Common Stock	0.59	0.75	0.2	0.81	0.75	0.75	0.78	0.57	0.78	0.8	0.95	0.79		0.88	0.8	0.78	0.7	0.72	0.59	0.68	0.65	0.61	0.69	0.78	0.78	0.59
Property Plant Equipment	0.71	0.87	0.45	0.98	0.94	0.93	0.88	0.71	0.89	0.95	0.97	0.96	0.88		0.91	0.95	0.86	0.87	0.74	0.82	0.87	0.75	0.76	0.91	0.96	0.74
Total Assets	0.7	0.92	0.69	0.94	0.93	0.83	0.79	0.74	0.95	0.91	0.85	0.96	0.8	0.91		0.94	0.88	0.75	0.6	0.67	0.64	0.6	0.73	0.93	0.94	0.6
Total Stockholder Equity	0.62	0.83	0.58	0.98	1.0	0.95	0.89	0.65	0.86	0.98	0.88	0.99	0.78	0.95	0.94		0.95	0.89	0.78	0.83	0.82	0.78	0.7	0.87	1.0	0.78
Cash	0.4	0.68	0.5	0.88	0.96	0.9	0.93	0.45	0.72	0.97	0.79	0.93	0.7	0.86	0.88	0.95		0.87	0.76	0.8	0.75	0.75	0.57	0.71	0.95	0.76
Non Current Assets Total	0.31	0.55	0.4	0.86	0.9	0.98	0.91	0.33	0.6	0.92	0.81	0.84	0.72	0.87	0.75	0.89	0.87		0.97	0.99	0.79	0.97	0.78	0.63	0.89	0.97
Non Currrent Assets Other	0.14	0.38	0.35	0.75	0.8	0.92	0.81	0.16	0.44	0.8	0.67	0.71	0.59	0.74	0.6	0.78	0.76	0.97		0.99	0.69	1.0	0.75	0.46	0.78	1.0
Good Will	0.26	0.48	0.36	0.81	0.85	0.96	0.86	0.26	0.54	0.86	0.77	0.78	0.68	0.82	0.67	0.83	0.8	0.99	0.99		0.76	0.99	0.8	0.56	0.83	0.99
Common Stock Shares Outstanding	0.59	0.66	0.19	0.83	0.8	0.84	0.82	0.57	0.65	0.84	0.85	0.81	0.65	0.87	0.64	0.82	0.75	0.79	0.69	0.76		0.69	0.5	0.7	0.82	0.68
Short Term Investments	0.17	0.4	0.35	0.76	0.8	0.92	0.8	0.19	0.45	0.8	0.68	0.71	0.61	0.75	0.6	0.78	0.75	0.97	1.0	0.99	0.69		0.77	0.48	0.78	1.0
Non Current Liabilities Total	0.43	0.62	0.62	0.75	0.7	0.8	0.65	0.42	0.67	0.7	0.7	0.68	0.69	0.76	0.73	0.7	0.57	0.78	0.75	0.8	0.5	0.77		0.68	0.7	0.75
Total Liab	0.9	1.0	0.63	0.93	0.84	0.74	0.65	0.92	1.0	0.81	0.86	0.91	0.78	0.91	0.93	0.87	0.71	0.63	0.46	0.56	0.7	0.48	0.68		0.87	0.46
Net Invested Capital	0.62	0.84	0.58	0.98	1.0	0.94	0.88	0.66	0.87	0.98	0.88	0.99	0.78	0.96	0.94	1.0	0.95	0.89	0.78	0.83	0.82	0.78	0.7	0.87		0.78
Long Term Investments	0.14	0.38	0.35	0.75	0.8	0.92	0.8	0.16	0.44	0.8	0.67	0.71	0.59	0.74	0.6	0.78	0.76	0.97	1.0	0.99	0.68	1.0	0.75	0.46	0.78

Click cells to compare fundamentals

BioNTech Account Relationship Matchups

High Positive Relationship

Inventory	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Total Stockholder Equity	+ 1.0	Retained Earnings
Net Invested Capital	+ 1.0	Retained Earnings
Total Liab	+ 1.0	Inventory
Net Invested Capital	+ 1.0	Total Stockholder Equity

High Negative Relationship

Not Found

BioNTech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	105.6M	494.6M	3.2B	1.6B	540.3M	964.9M
Total Current Liabilities	138.1M	606M	3.5B	3.0B	2.1B	1.5B
Other Liab	205.6M	97.1M	109.8M	283.9M	326.5M	200.3M
Net Tangible Assets	179.6M	406.5M	1.2B	11.7B	13.5B	14.1B
Retained Earnings	(424.8M)	(409.6M)	9.9B	18.8B	19.8B	20.8B
Accounts Payable	20.5M	102.3M	160M	204.1M	354M	371.7M
Other Assets	2.4M	168.2M	22.2M	249.2M	286.6M	300.9M
Net Receivables	20.2M	166.4M	12.4B	7.1B	2.2B	3.4B
Inventory	12.1M	64.1M	502.5M	439.6M	357.7M	217.8M
Other Current Assets	7.0M	89M	113.4M	271.9M	280.9M	294.9M
Other Stockholder Equity	318.6M	691.5M	1.5B	1.8B	2.0B	2.1B
Total Current Assets	560.2M	1.7B	15.1B	21.9B	19.5B	20.5B
Property Plant Equipment	116.0M	148.1M	326M	520.4M	598.5M	628.4M
Total Assets	797.6M	2.3B	15.8B	23.3B	23.0B	12.1B
Total Stockholder Equity	493.5M	1.4B	11.9B	20.1B	20.2B	21.3B
Cash	519.1M	1.2B	1.7B	13.9B	11.7B	12.2B
Non Current Assets Total	237.5M	651.7M	758.5M	1.4B	3.5B	3.7B
Non Currrent Assets Other	2K	1.0M	800K	6.5M	83.4M	87.6M
Good Will	3.0M	53.7M	57.8M	61.2M	362.5M	380.6M
Common Stock Shares Outstanding	226.8M	241.5M	242.5M	243.2M	237.7M	260.6M
Short Term Investments	1.7M	137.2M	381.6M	189.4M	4.9B	5.1B
Non Current Liabilities Total	166.0M	340.8M	455.5M	272.9M	689.9M	400.6M
Total Liab	304.2M	946.8M	3.9B	3.2B	2.8B	2.1B
Net Invested Capital	493.5M	1.4B	12.2B	20.3B	20.5B	21.5B
Capital Stock	232.3M	246.3M	246.3M	248.6M	285.9M	259.5M
Net Working Capital	422.0M	1.1B	11.6B	19.0B	17.5B	9.1B
Intangible Assets	86.5M	109.8M	144.6M	158.5M	804.1M	844.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:

How To Invest In BioNTech

Details

Is BioNTech Stock a good investment?

Details

What is BioNTech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioNTech Net Receivables vs Accounts Payable Analysis

Net Receivables vs Accounts Payable

Net Receivables vs Accounts Payable Correlation Analysis

Correlation Coefficient

Net Receivables

Accounts Payable

BioNTech fundamental ratios Correlations

BioNTech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNTech fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY